Compare STAA & ADNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STAA | ADNT |
|---|---|---|
| Founded | 1982 | 2016 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.5B |
| IPO Year | N/A | N/A |
| Metric | STAA | ADNT |
|---|---|---|
| Price | $23.18 | $19.56 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 10 | 10 |
| Target Price | ★ $24.56 | $21.90 |
| AVG Volume (30 Days) | ★ 1.5M | 1.1M |
| Earning Date | 02-10-2026 | 01-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $230,591,000.00 | ★ $14,535,000,000.00 |
| Revenue This Year | N/A | $1.49 |
| Revenue Next Year | $21.97 | $2.15 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.50 | $10.04 |
| 52 Week High | $30.81 | $26.16 |
| Indicator | STAA | ADNT |
|---|---|---|
| Relative Strength Index (RSI) | 41.35 | 49.76 |
| Support Level | $22.90 | $19.09 |
| Resistance Level | $23.74 | $19.60 |
| Average True Range (ATR) | 1.18 | 0.54 |
| MACD | -0.11 | 0.15 |
| Stochastic Oscillator | 8.84 | 65.65 |
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.
Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment. Adient is a leading seating supplier to the industry with about a midteens share of the global market including unconsolidated joint venture business. Its share in China is around 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated revenue from joint ventures was about $3.5 billion in fiscal 2025 and consolidated China revenue was $1.3 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2025 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $14.5 billion.